NBI-827104 is under clinical development by Neurocrine Biosciences and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NBI-827104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NBI-827104 overview

NBI-827104 is under development for the treatment of epilepsy. The drug candidate is administered through the oral route and formulated as film coated tablet and capsule. It is a small molecule which acts by targeting T-type calcium channel.

It was under development for the treatment of pediatric subjects with epileptic encephalopathy and essential tremor.

Neurocrine Biosciences overview

Neurocrine Biosciences (Neurocrine) discovers, develops, and sells pharmaceutical products for the treatment of neurologic, psychiatric, and endocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). The company’s other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids, and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. The company also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.

For a complete picture of NBI-827104’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.